Compare TXMD & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXMD | IRIX |
|---|---|---|
| Founded | 2008 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 23.2M |
| IPO Year | 2012 | 1996 |
| Metric | TXMD | IRIX |
|---|---|---|
| Price | $2.18 | $0.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.6K | ★ 48.7K |
| Earning Date | 05-12-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.61 | 8.47 |
| EPS | ★ N/A | N/A |
| Revenue | $1,761,000.00 | ★ $41,593,000.00 |
| Revenue This Year | $427.09 | $10.43 |
| Revenue Next Year | N/A | $7.32 |
| P/E Ratio | $90.64 | ★ N/A |
| Revenue Growth | ★ 35.25 | N/A |
| 52 Week Low | $0.84 | $0.79 |
| 52 Week High | $2.95 | $1.65 |
| Indicator | TXMD | IRIX |
|---|---|---|
| Relative Strength Index (RSI) | 37.04 | 23.19 |
| Support Level | $1.05 | $0.87 |
| Resistance Level | $2.35 | $1.22 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 2.67 | 8.43 |
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.